🇺🇸 FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8404638

Dimer VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8388963

Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8357371

Methods for treating hypercholesterolemia using antibodies to PCSK9

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8354103

Human antibodies to human angiopoietin-like protein 4

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8343737

Cell culture compositions capable of producing a VEGF-binding fusion polypeptide

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8337839

High affinity human antibodies to human IL-4 receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8338135

High affinity human antibodies to human IL-4 receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8329181

Methods for treating B-cell lymphoma by administering an anti-CD20 antibody

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8309088

Method of treating osteoarthritis with an antibody to NGF

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8298532

Fusion polypeptides capable of activating receptors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8192741

Method of treating rheumatoid arthritis with an anti-IL-6R antibody

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 05 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8183014

High affinity antibodies to human IL-6 receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8158581

IGF-1 fusion polypeptides and therapeutic uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8148107

High affinity human antibodies to human nerve growth factor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8114394

Use of IL-1 antagonists to treat gout

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8110546

VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 07 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8105805

High affinity human antibodies to human IL-18 receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 31 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8101724

High-affinity human antibodies to human protease-activated receptor-2

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8097713

Nucleic acid molecules which encode human anti-CD20 antibodies and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8092803

VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8092802

High affinity human antibodies to human IL-4 receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8084234

Isolated nucleic acid molecules encoding a fusion protein capable of binding VEGF

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 27 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8080248

Method of treating rheumatoid arthritis with an IL-6R antibody

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 20 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8075887

High affinity human antibodies to human IL-4 receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 13 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted